Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeuralSTEM Biopharmaceuticals Ltd.

This article was originally published in Start Up

Executive Summary

Many companies have joined the quest for a renewable source of neurons. NeuralSTEM Biopharmaceuticals claims to have identified multipotential neural stem cells, cells capable of deelping into neurons, oligodendrocytes and astrocytes.

You may also be interested in...



Neuronyx Inc.

The time is right to get into the blossoming field of stem cells, believes the high-profile founder of Neuronyx Inc., Hubert Schoemaker, PhD. Fresh from the sale of Centocor, the first-generation biotech that he co-founded, Shoemaker founded Neuronyx in 1999 to develop stem cell-based therapies for neurological disorders.

Planet Neuron: Start-Ups in Neurobiology

New drug discovery tools promise to shorten the distance between mouse and man while new neurology drugs remain on the distant horizon. Meanwhile, licensing keeps start-ups going.

Wound Solutions Ltd.

Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel